Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine
2018
Background
Mesenchymal stromal cells (MSCs) are promising cell therapy candidates. Clinical application is considered safe. However, minor side effects have included thromboembolism and instant blood-mediated inflammatory reactions suggesting an effect of MSC infusion on hemostasis. Previous studies focusing on plasmatic coagulation as a secondary hemostasis step detected both procoagulatory and anticoagulatory activities of MSCs. We now focus on primary hemostasis and analyzed whether MSCs can promote or inhibit platelet activation.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
64
References
15
Citations
NaN
KQI